Introduction and hypothesis Weight-loss has been demonstrated to result in an improvement in fecal incontinence (FI) severity; however, there is a paucity of data addressing the differential impact of FI on the quality of life (QOL) and results of diagnostic testing across BMI categories. We wished to evaluate symptom distress, QOL, and diagnostic testing parameters among normal, overweight, and obese women with fecal incontinence. Methods Women undergoing evaluation for FI between 2003 and 2012 were identified. Participants completed validated, symptom-specific distress, impact, and general QOL measures including the Modified Manchester Questionnaire (MMHQ), which includes the Fecal Incontinence Severity Index (FISI), and the mental and physical component summary scores, MCS and PCS, respectively, of the Short Form-12. Anorectal manometry measures were also included. Multivariate regression analyses were performed.
Introduction
Fecal incontinence (FI), as defined by the International Consultation on Incontinence, is the involuntary loss of flatus, liquid or solid stool that is a social or hygienic problem; anal incontinence is the involuntary loss of flatus [1] . These conditions affect both men and women; however, they are seen more commonly in women. Depending upon the population in which it is studied and its definition, fecal incontinence prevalence rates vary between 2 % and 10 % [2, 3] . FI has a significant impact on both patients and society. It negatively affects patients' quality of life (QOL) and results in embarrassment, social isolation and loss of self-esteem [4] . FI also represents a significant financial burden to the US healthcare system and is the second leading cause of nursing home admissions [5, 6] .
The etiology of FI is multifactorial resulting from direct sphincter injury, denervation of the anal sphincter and/or pelvic floor [7] [8] [9] , changes in stool consistency, or a combination of these [10] . Risk factors for FI in women include vaginal delivery, obstetric trauma, increasing age, urinary incontinence, pelvic floor dysfunction, chronic diarrhea or loose stool, and disorders resulting in sensory impairment.
Diagnostic testing of FI in women includes the use of anorectal manometry, endoanal ultrasound, pudendal nerve terminal motor latency, anal sensation, electromyography, ambulatory manometry, balloon expulsion test, defecography, and magnetic resonance imaging [11, 12] . Anorectal manometry evaluates resting and squeeze sphincter pressures corresponding to the internal and external anal sphincter tone respectively. It also measures the pressure/volume at first sensation (rectal sensory threshold), urgency to defecate (sensation of fullness), and maximum capacity (maximum tolerable volume) [11] . Anorectal manometry can play an important role in behavioral modification via biofeedback and muscle retraining in the treatment of FI. Endoanal ultrasound allows for direct assessment of the anal sphincter anatomy to determine if a disruption is present that could be surgically repaired.
Obesity is a major public health issue in the United States. It is estimated that greater than 50 % of women in the United States are overweight or obese and the prevalence of obesity is rising by 6 % per year [13, 14] . Obesity is a modifiable risk factor of FI [15] [16] [17] . Weight loss has been demonstrated to result in an improvement in both the number and severity of FI episodes [18] [19] [20] . However, there is a paucity of data addressing the true impact of FI on QOL and in understanding if there are differential findings of diagnostic testing in the obese compared with women with a normal body mass index (BMI) suffering from FI.
The aim of this study was to characterize differences in symptom distress and the impact on QOL as well as baseline anorectal diagnostic testing findings, specifically anal manometry, among normal, overweight, and obese women with FI/AI.
Materials and methods
The study was a retrospective cohort design. After obtaining approval from the Institutional Review Board, women who underwent evaluation for FI at our institution between 2003 and 2012 were identified. Patients were included in the study if they had evidence of FI as demonstrated by a positive inquiry upon interview regarding incontinence of liquid or solid stool. In addition, women indicating any positive response to validated measures assessing the presence of solid, liquid, or gas incontinence were included.
Patients completed baseline anorectal manometry measures, resting sphincter tone, sphincter squeeze pressure, and rectal capacity, baseline endoanal ultrasound, measuring whether the external or internal sphincters were intact, and validated intake questionnaires assessing symptom-specific distress and impact on QOL. Patient's subjective evaluation included the Modified Manchester Questionnaire (MMHQ), which includes the Fecal Incontinence Severity Index (FISI), and the Short Form 12 (SF-12), which includes the Mental Component Summary Score (MCS) and Physical Component Summary Score (PCS) [21, 22] .
Participants were stratified into one of three groups based on the World Health Organization BMI classifications: normal weight (BMI <25 kg/m 2 ), overweight (BMI ≥25 and <30 kg/m 2 ), and obese (≥30 kg/m 2 ) [23] . The primary aim was to evaluate the differences in patient symptom perception and impact on QOL among the three groups. The secondary aim was to evaluate the differences in baseline anorectal manometry measurements among BMI classifications as inferences regarding pathophysiology or mechanism may be made. Demographic and medical history data were collected on each patient including: age, race/ethnicity, smoking, hypertension, pulmonary disease, diabetes, prior colorectal surgery, hysterectomy, cholecystectomy, and history of sphincter disruption.
Patient characteristics were examined across the three BMI groups using one-way analysis of variance (ANOVA) for quantitative measures and Chi-squared tests of association for categorical measures. Both subjective and objective study outcomes were compared across the three BMI groups using one-way ANOVA. Multivariate regression analyses controlling for characteristics significantly differing across BMI groups, including race, history of medical comorbidities, cholecystectomy, and anal sphincter disruption, were subsequently performed. All statistical tests were twosided and because of multiple hypothesis testing were evaluated at a 0.01 level of significance. Statistical analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
Four hundred and seven women with evaluable data presenting for FI evaluation during the defined study period were included in this analysis: 160 obese, 123 overweight, and 124 with normal BMI. Overall, patients were predominantly white (85 %), and had a mean age ± SD of 56±13 years. The proportion of women with diabetes (p<0.001), hypertension (p<0.0001), pulmonary disease (p=0.003), and cholecystectomy (p<0.0001) differed significantly across all three BMI groups. Obese women had higher rates of diabetes, hypertension, respiratory disease, and cholecystectomy than non-obese women. The proportion of Caucasians differed across the BMI groups, with fewer obese Caucasians than non-obese Caucasians (p=0.001). There were no additional statistically significant differences in baseline characteristics among the three groups (Table 1) .
In univariate analyses, there were no significant differences among BMI groups in FI-specific symptom distress or impact by baseline MMHQ and FISI score ( Table 2) . Significant differences were observed among BMI groups in both the MCS (p=0.002) and PCS (p<0.001) subscales of the SF-12. In multivariate analyses controlling for race, diabetes, cholecystectomy, hypertension, pulmonary disease, and anal sphincter disruption, there continued to be no difference in symptom-specific distress and impact across BMI groups. Similarly, no differences were observed for the MCS or PCS subscale SF-12 scores (p=0.014 and p=0.246 respectively).
Significant differences were seen in both resting and squeeze pressures across the three BMI groups (p<0.0001; Table 3 ). These differences in resting and squeeze pressures remained significant (p<0.0001, p=0.005 respectively) in multivariate regression models adjusting for race, diabetes, sphincter disruption, cholecystectomy, hypertension, and pulmonary disease. Variations in rectal capacity were not observed among BMI groups.
Discussion
As FI is such a devastating issue with its resultant influence on the quality of life, it was interesting to find no differential effect of symptom-specific distress and impact among the three BMI cohorts as measured by the MMHQ and FISI. Given that obesity can have a significant influence on emotional and general health, it was also surprising to observe no differences between PCS and MCS subscales of the SF-12 among the three BMI cohorts after controlling for other known medical comorbidities associated with obesity.
The BMI is a known modifiable risk factor of FI and therefore, it is unclear why differences were not seen in symptom distress severity across the three cohorts. Several studies have investigated the effect of nonsurgical and surgical weight loss and have demonstrated that FI symptom improvement occurs with weight loss [19, 24] . This would infer that we may have seen a difference in symptom distress severity among our BMI cohorts. However, it may be that this improvement in symptoms is a result of the change in a patient's BMI and not a patient's BMI category. Thus, comparing our cohorts and the symptom distress that those respective patients experienced at a singular point in time may not be expected to mirror the results of studies that evaluated change in symptom distress with a concomitant change in BMI over time.
Initially, univariate analysis of obese women with FI did reflect a worse general mental and physical impact on quality of life; however, this effect was nullified for both the MCS and PCS scores in multivariate regression models adjusting for race, diabetes, sphincter disruption, cholecystectomy, hypertension, and pulmonary co-morbidities. Though not statistically significant at a 0.01 level of significance in the regression model, the effect of BMI class on MCS scores trended toward statistical significance (p = 0.014), with covariate-adjusted MCS means decreased with increasing BMI. In looking at SF-12 scores from a sampling of the general US population where normal MCS and PCS scores are 50, those with serious physical conditions had a mean PCS and MCS of 38.75±1.0 and 52.51±0.8 respectively [25, 26] . Our study population demonstrated overall lower scores on both the PCS and MCS subscales compared with the normal population, 41.2±11.7 and 42.1±12.0 respectively. It is not surprising that co-morbid conditions alone lower PCS and MCS scores in this population of women, and clearly when controlling for these variables among this study Diagnostic testing with anal manometry showed that obese women with fecal incontinence had higher baseline anal resting tone and squeeze pressures compared with normal women. This variation in anal manometry measures persisted when controlling for race, diabetes status, hypertension, pulmonary disease, history of cholecystectomy, and whether the patient had an intact or disrupted anal sphincter. The mechanism behind this observation is unclear and data addressing this issue are scarce.
However, there have been studies that have looked at the impact that obesity has on the evaluation of the urinary sphincter. One such study showed that obese women report worse symptom distress and quality of life despite better urethral function on baseline urodynamics [29] . The authors in that study suggested that while obese women had higher leak point pressures, they also had higher resting pressures. This may reflect a decreased threshold to leak. The authors attributed this finding to Henneman's principle, postulating c Effect remains significant (p<0.0001) in multivariate regression models adjusting for race, diabetes, sphincter disruption, cholecystectomy, hypertension, and pulmonary co-morbidity. Obese is significantly greater than both overweight (p<0.0001) and normal (p<0.0001) d Effect remains significant (p=0.005) in multivariate regression models adjusting for race, diabetes, sphincter disruption, cholecystectomy, hypertension, and pulmonary co-morbidity. Obese is significantly greater than both overweight (p=0.004) and normal (p=0.007) e Effect remains nonsignificant (p=0.062) in multivariate regression models adjusting for race, diabetes, sphincter disruption, cholecystectomy, hypertension, and pulmonary co-morbidity that the higher resting tone required more muscle fiber recruitment to maintain resting pressure [30] . As a result, there were less motor units available to recruit to prevent urinary leakage. Although considered a potential theory, an analogous situation may be seen here as an explanation for the variation in anorectal manometry measurements; however, further studies to help further understand the pathophysiology are needed. This study has inherent limitations owing to its retrospective design; however, all participants completed questionnaires on their own as a part of the general clinic intake and standardized protocols were performed with the diagnostic testing. The data presented represents the responses of women with fecal incontinence within each of the three BMI groups upon their respective presentation for evaluation; thus, conclusions regarding how changes in BMI affect fecal incontinence symptom impact, distress, and patient quality of life over time cannot be generated. Furthermore, the main statistical limitation is of multiple hypothesis testing; however, we defined statistical significance at the 0.01 level and modeled at the association of symptoms and diagnostic testing variables and BMI held controlling for confounders. Strengths of this study include a large study population with robust clinico-demographic characterization. A spectrum of validated measures was utilized to characterize both symptom-specific and the general impact on quality of life. Finally, the clinical question is particularly pertinent with the markedly increasing prevalence of obesity world-wide.
Owing to the significant impact FI has on quality of life and the current limitations with regard to long-term treatment success for FI, it is imperative that more robust prospective studies are pursued to improve our understanding of the pathophysiology of FI in obese women. A better understanding of variations in diagnostic evaluation and treatment approaches of FI in obese women including weight loss, may have an impact on the management of this complex condition.
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